2012-02-11 04:02:28 - Fast Market Research recommends "Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012" from Global Markets Direct, now available

Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012', provides an overview of the Organophosphate And Carbamate Poisoning therapeutic pipeline. This report provides information on the therapeutic development for Organophosphate And Carbamate Poisoning, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Organophosphate And Carbamate Poisoning. 'Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's

team.


Full Report Details at
- www.fastmr.com/prod/330178_organophosphate_and_carbamate_poisoni ..


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Organophosphate And Carbamate Poisoning.
* A review of the Organophosphate And Carbamate Poisoning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Organophosphate And Carbamate Poisoning pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Organophosphate And Carbamate Poisoning.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Organophosphate And Carbamate Poisoning pipeline depth and focus of Organophosphate And Carbamate Poisoning therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Organophosphate And Carbamate Poisoning Overview
Therapeutics Development
An Overview of Pipeline Products for Organophosphate And Carbamate Poisoning
Organophosphate And Carbamate Poisoning Therapeutics under Development by Companies
Organophosphate And Carbamate Poisoning Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Organophosphate And Carbamate Poisoning Therapeutics - Products under Development by Companies
Organophosphate And Carbamate Poisoning Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Organophosphate And Carbamate Poisoning Therapeutics Development
MicroDose Therapeutx, Inc.
Organophosphate And Carbamate Poisoning - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Atropine Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates
Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products
Organophosphate And Carbamate Poisoning - Product Development Milestones
Featured News & Press Releases
Jun 07, 2011: MicroDose Therapeutx Announces Successful Completion Of Phase I Pilot Study Of Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning
Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day
Jun 08, 2010: Protalix Completes Phase I Clinical Trial For PRX-105
Sep 23, 2009: MicroDose Therapeutx Announces Initiation Of Phase I Study With Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Organophosphate And Carbamate Poisoning, H1 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=330178&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.